The August 10 deadline for a refinancing/sale transaction is the immediate catalyst. Expect a material announcement — likely an equity raise, debt restructuring, or asset sale — within the next week. Failure to secure a deal would trigger an event of default, potentially wiping out equity holders. Monitor for press releases and trade OTC scenarios accordingly.
Price Chart
Executive Summary
BioXcel Therapeutics entered its Eleventh Amendment to the Oaktree credit agreement, deferring a $9.0M payment to August 31, 2026, reducing the minimum liquidity covenant from $7.5M to $6.25M, and requiring the company to sign definitive agreements for an Acceptable Transaction (full repayment or alternative capital solution) by August 10, 2026. This is a clear distress signal: the lender is granting a short Band-Aid extension while tightening the timeline, creating substantial going-concern risk for a $25M market-cap biotech.
Key Facts
- Payment of $9,016,914.47 (principal + interest originally due June 30, 2026) deferred to August 31, 2026.
- Minimum liquidity covenant reduced from $7.5M to $6.25M.
- Company must enter definitive agreements for an Acceptable Transaction by August 10, 2026.
- Compensation arrangements frozen and non-ordinary-course payments prohibited through August 31, 2026.
- This is the Eleventh Amendment to the credit agreement, reflecting repeated covenant relief.
Financial Impact
Deferred principal and interest payment of $9,016,914.47; liquidity floor lowered to $6.25M; company essentially must refinance or sell assets by August 10, 2026.
Risk Factors
- Inability to consummate an Acceptable Transaction by August 10 could lead to an event of default and potential bankruptcy.
- Repeated amendments signal worsening financial condition and limited lender patience.
- Severe dilution risk if the company completes an equity raise near current depressed levels.
- Nasdaq continued listing risk given micro-cap status and potential going-concern disclosure.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001104659-26-089436 |
| Document: tm2622012d1_8k.htm | 0001104659-26-089436 |
| Document: 0001104659-26-089436-index-headers.html | 0001104659-26-089436 |
| Document: 0001104659-26-089436-index.html | 0001104659-26-089436 |
| Document: 0001104659-26-089436.txt | 0001104659-26-089436 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 1, 2026 7w ago | 8-K | $0.1370 | awaiting T+60 | — | — |
Aug 28, 2026 8w ago | Press Release | $0.1814 | awaiting T+60 | — | — |
Aug 25, 2026 8w ago | 8-K | $0.7422 | awaiting T+60 | — | — |
Aug 11, 2026 10w ago | 8-K | $0.9320 | awaiting T+60 | — | — |
Aug 3, 2026 12w ago | 8-K | $0.8480 | awaiting T+60 | — | — |
Jul 6, 2026 16w ago | 8-K | $1.10 | awaiting T+60 | — | — |
May 22, 2026 22w ago | Insider Cluster | $1.22 $0.8274 | ▲ +32.18% | ▲ +34.91% | — |
May 20, 2026 22w ago | 144 | $1.14 $0.8900 | ▼ −21.93% | ▼ −26.23% | — |
May 15, 2026 23w ago | 8-K | $1.14 $0.9319 | ▼ −18.25% | ▼ −22.77% | — |
May 15, 2026 23w ago | Press Release | $1.14 $0.9319 | ▲ +18.25% | ▲ +22.77% | — |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers